Navigation Links
Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial
Date:3/31/2009

Central Texas man receives groundbreaking therapy days after heart attack

AUSTIN, Texas, March 31 /PRNewswire/ -- On March 30, the Heart Hospital of Austin treated the first patient in the world enrolled in a groundbreaking Phase II study designed to test the effectiveness and safety of administering adult stem cells intravenously to repair damaged heart tissue after a heart attack.

Dr. Roger Gammon, a cardiologist with Austin Heart cardiology group treated a 58-year-old Central Texas man with the experimental adult stem cell treatment, just days after his first heart attack.

"We are excited to be the first to treat a patient in this groundbreaking study and to lead the way in this important research," states Dr. Gammon "Austin Heart and the Heart Hospital of Austin were selected because of their proven history of excellence in cardiovascular research and strong performance in the earlier Phase I trial," Gammon adds.

Prochymal(R) is being evaluated for its ability to treat heart damage caused by a heart attack. The active ingredient in the new treatment is adult Mesenchymal Stem Cells (MSCs). The cells in the drug are from normal, healthy adult volunteer donors and are not from a fetus, embryo or animal. MSCs have the ability to develop into other types of cells and generate new tissue, including heart muscle. Prochymal(R) is a product of Osiris Therapeutics, Inc.

"There's a lot of enthusiasm in the cardiovascular community about the potential of stem cell therapies for treating heart disease. Earlier studies have established confidence in the safety of the therapy, but more research is needed to study its effectiveness," states Gammon.

In this prospective, double-blind, placebo-controlled Phase II study, Heart Hospital of Austin and Austin Heart researchers will study patients to determine the effectiveness and safety of Prochymal(R) for treating heart damage resulting from a heart attack. Heart Hospital of Austin is one of approximately 40 institutions in the United States and Canada participating in the study. Patients that participate in the study must receive the treatment within seven days of a heart attack. The stem cell treatment is administered intravenously and typically takes less than an hour to complete.

Prochymal(R) is currently an investigational therapy and is not yet approved by the Food and Drug Administration.

After a Heart Attack:

In 2009 alone, more than half a million Americans will have their first attack. According to the American Heart Association, 18% percent of men and 35% of women will have another heart attack within six years of their event.


'/>"/>
SOURCE Heart Hospital of Austin
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. ATS Medical Expands Open Pivot Heart Valve Offerings
3. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
4. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
5. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
8. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
9. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
10. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):